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ABSTRACT
Public interest and scientific inquiry are currently bringing psychedelic research back into
the spotlight after a decades-long respite from clinical human trials. A majority of the research
during this recent renaissance has surrounded applications of psychedelics in the fields of mental
health. Less attention is being focused to other research areas where psychedelics may also prove
informative, such as cognition and information processing. A common trend taking place is the
act of administering very small doses of psychedelics as a potential cognitive enhancer, called
microdosing. With less research being focused on these areas however, it is not well documented
whether the effects of microdosing provide consistent or measurable results. The current study
aimed to test the effects of microdosing on information processing using a research design
originally administered in stimulant research on attention. Participants were anonymously
recruited from various psychedelic microdosing forums online (N = 4), and compared in a
between-subjects design against a separate sample who did not microdose (N = 10). Results from
the task did not yield significant effects, possibly due to an underpowered sample. However,
trends in the results highlighted the potential for an effect opposite to that of the proposed
hypothesis. Recommendations have been provided for additional research to improve upon the
design of the study and to also propose alternate hypotheses regarding the effects microdosing on
information processing as well as other areas of study that may also benefit from microdosing
research.
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INTRODUCTION
Current Research and Applications
It is now more common to see news segments and journal articles discussing clinical
research conducted on psychedelic compounds. Even from a regulatory perspective, the United
States Food and Drug Administration has gone so far as to place psilocybin research into an
accelerated schedule for new treatment developments (Weir, 2020). This resurgence in interest as
tools for psychiatry and psychology is something which largely contrasts previous decades
leading back to the 1970s, when prohibition of many psychedelic compounds was formalized
through the passing of the Controlled Substances Act (Lampe, 2021). It is a virtuous endeavor
that many researchers have long awaited the chance to use psychedelics in establishing new
treatments for psychological disorders like Major Depressive Disorder, substance addiction, and
end-of-life distress (Weir, 2020). However, because of the long interruption, there are many gaps
we appear to be jumping over in our understanding about how psychedelic compounds may
interface with human functions, such as through the study of cognition and perception. It could
even be said that knowledge of the fundamental effects these substances have should precede the
findings we gain for clinical use, if we are to ensure long-term positive outcomes in the health of
our nation and species.
While cognition is not a direct focus for the current paradigm of psychedelic research,
determining how these substances affect our mental capabilities is nonetheless benefitted by the
clinical research being performed. The full context of psychedelic therapy greatly exceeds the
bounds of this discussion due to its extensively rich history spanning an unknown number of
cultures over thousands of years. Thus, the focus will remain on several methods presently being
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reported in Western literature that are relevant in providing some context for the current research
landscape. Such methods are benefitted both by the clinical results that are emerging from such
fields of study, as well as growing public interest in the topic.
First, is the framework for moderate-to-high dose psychedelic sessions, usually
accompanied by follow-up psychotherapy. This is the case for work conducted by the
Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is currently in ongoing
Phase 3 FDA clinical trials for treatment of Posttraumatic Stress Disorder using
methylenedioxymethamphetamine, a compound with its own unique array of neurobiological
effects (MAPS, n.d.), but which has faced similar scrutiny to psychedelics in the past. Another
active clinical research group is the Johns Hopkins Center for Psychedelic & Consciousness
Research, headed by Dr. Roland Griffiths and Dr. Matthew Johnson. Their work focuses on a
range of applications for psychedelic therapy, from smoking cessation, depression, and more
(Johns Hopkins Center for Psychedelic & Consciousness Research, n.d.). Coinciding with the
clinical studies, functional brain imaging is being implemented to better specify underlying
neural networks that are affected during the psychedelic experience. The sites for this work
include the Centre for Psychedelic Research at Imperial College of London, headed by Dr.
Robin-Carhart Harris (Centre for Psychedelic Research, n.d.), and the Neurophenomenology of
Consciousness group at the University of Zurich, headed by Dr. Franz Vollenweider, who
collaborates jointly between the university and the Heffter Research Center (Department of
Psychiatry, Psychotherapy and Psychosomatics, n.d.).
The second method of psychedelic use that has gained traction, referred to as
microdosing, is a possible means to test the cognitive effects of psychedelics and will be the
main focus of this study. Microdosing involves taking fractional doses of psychedelics relative to
2

what might be considered a true psychedelic dose, where the user’s intention is not surrounded
around experiencing any sort of intense visionary effects from the drug. Instead, the subjective
reports gathered from case studies and preliminary qualitative research into microdosing
highlight a potential for more manageable shifts in an individual’s perception and behavior, such
as increasing work productivity or improvements to mood (Fadiman, 2019; Polito & Stevenson,
2019). Other self-reports from users describe effects like increased focus and even a subjective
enhancement to visual acuity (Andersson & Kjellgren, 2019).
Experimental testing of the effects of microdosing through 2020 had still remained
limited in frequency and was mainly based on questionnaire designs, due in part to the legal
hurdles psychedelic research faces within a controlled laboratory setting. In order to conduct
laboratory experiments with human subjects and verifiable substances, researchers in many
countries are required to receive the approval of law enforcement agencies, adherence to rigorous
protocols that involve strict accountability for the security and storage of the substances, and
additional fees to register for such research (Altneau, 2020). This is specifically true for research
in the United States, where these drugs are classified within the most restrictive scheduling class
- Schedule I - and where medical use is still designated as not acceptable (Lampe, 2021). This
prolongs the period of time it takes to determine whether microdosing effects are actually
present, or if instead, perceived benefits may be attributable to a placebo effect at work
(Bornemann, 2020).
Some support for the presence of a placebo effect has just now begun to surface within
microdosing research. In a new study published after the development of this project, findings of
such placebo effect were observed by researchers at the Imperial College London and the
Beckley Foundation (Szigeti et al., 2021). The design utilized a novel “citizen-science” initiative
3

whereby remote-based participants followed specific instructions to self-blind their microdose
administration before completing self-report questionnaires and cognitive tests online (Szigeti et
al., 2021). No statistically significant changes were identified between microdosing and control,
although there were some observed trends in greater improvements for the microdosing group
over the five-week study period (Szigeti et al., 2021). It was suggested that given the unique
nature of this novel study design outside of a clinical testing environment, the final sample of
191 participants still may have been underpowered (Szigeti et al., 2021). The study is interesting
for a few reasons other than the direct outcome. From a confidentiality and cost perspective,
research designs that can effectively utilize remote participation alleviates some of the traditional
issues that have plagued psychedelic research. Also, through the creation of instructable methods
that can be distributed to large audiences, real-world ecological conditions under which
individuals partake in microdosing can be better emulated, potentially improving
generalizability. However, it should also be noted that the researchers emphasized various
limitations exist as a trade-off, since there was no ability to verify dosage, substance purity, or to
test whether participants completed the blinding procedures exactly as instructed (Szigeti et al.,
2021). The citizen-science approach of self-blinding prior to performing various behavioral tasks
and assessments is a promising new development in this field of research, should some of its
main limitations be improved upon for future studies.

Biological and Neurocognitive Bases for Studying Psychedelics in Vision Sciences
While clinical and cognitive research on the effects of psychedelics is still developing,
from a biological perspective, much more is known about psychedelic action in the mammalian
brain. Most prominently talked about regarding the neurobiology of psychedelics is the particular
4

receptor site activated by the classical psychedelics (lysergic acid diethylamide [LSD],
psilocybin, and N,N-Dimethyltryptamine). Classical psychedelics are shown to have high affinity
at the serotonergic 5HT2A receptor site, where they act agonistically (Maisto et al., 2017). To
briefly provide some clarity for terminology such as receptor site affinity, the basis for chemical
communication in the nervous system relies on messenger molecules, called neurotransmitters
(NT), which are sent and received between neurons. Neurons possess specific receptor proteins
embedded in their membranes that are selective and reactive to particular NT. In a case where a
NT binds selectively to another neuron’s particular receptor, the NT can be classified as a ligand
to that receptor, and as such, has some level of affinity for it. For 5HT receptors, the naturally
produced, or endogenous, ligand is Serotonin (5HT). 5HT2A is a member of the 5HT receptor
family, and is found in both the central and peripheral nervous system, including cortical and
subcortical regions like the neocortex, claustrum, and basal ganglia, serving a large range of
functions (Hoyer et al., 2002). Specific to 5HT’s role in vision, research shows that the 5HT2A
receptor comprises a majority of serotonergic functioning in the primate visual system, where it
modulates neuronal impulses sent from the lateral geniculate nucleus in the thalamus (Shimegi et
al., 2016). Out of seven known families of 5HT receptor types, the 5HT2A and 5HT1B receptors
have been identified as key players of serotonergic activity in multiple cortical layers of the
visual system. Here, 5HT2A receptors are prominently mapped to primary visual cortex V1, and
extrastriate layers V2 – V4 (Shimegi et al., 2016).
5HT2A activation by classical psychedelics is thought to play an important role in the
psychedelic imagery that accompanies such experiences, like what occurs under LSD (Roseman
et al., 2016). Research on effects of the South American preparation Ayahuasca, containing the
psychedelic indole alkaloid DMT (Carbonaro & Gatch, 2016), similarly indicate activation of
5

this receptor site in relation to psychedelic imagery (Valle et al., 2016). These reports are further
validated by more focused studies of the 5HT2A receptor whereby different conditions involving
the use of psilocybin, as well as a known 5HT2A antagonist, ketanserin, were utilized. In such
study, it was shown that when ketanserin was administered, the visual effects produced by
psilocybin were no longer present (Kometer, et al., 2013). In general then, these effects on visual
imagery by classical psychedelics highlight underlying changes occurring within the visual
system, and which may also create further modulations downstream for cognitive processes
linked to visual perception.
Along with the role that 5HT2A receptor sites appear to have in early visual processing,
there is already evidence that serotonergic modulation has implications for attentional
processing. The administration of selective serotonin reuptake inhibitor (SSRI) medications for
instance, such as escitalopram, has been shown to impact performance in a variety of
assessments that encompass sustained attention, selective attention, and divided attention
(Wingen, Kuypers, & Ramaekers, 2006). Evidence seems to indicate that increased 5HT is
generally correlated to inhibition of attention tasks, meaning that as 5HT levels increased,
performance on the task decreases (Wingen, Kuypers, & Ramaekers, 2006; Oranje, et al., 2008;
Tian, Schmidt, & Lambe, 2016). Given that classical psychedelics are 5HT2A agonists and may
modulate cognition in a currently unknown manner, the anecdotal reports of microdosing
enhancing attention, do warrant further investigation.
Switching focus to the cortical networks associated with attention, the prefrontal cortex
(PFC) has been specifically associated with attention tasks. Mapping of the PFC has shown that
there is robust 5HT innervation leading to multiple regions of the PFC (Linley, Hoover, &
Vertes, 2013). 5HT1A and 5HT2A have also been shown to inhibit the function of Layer 6 (L6)
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pyramidal neurons that are located in the mammalian medial PFC - a region considered vital for
top-down processing of attention (Tian, Schmidt, & Lambe, 2016). Even prior to activity in the
PFC, early modulation of visual attention, such as for stimulus selection and filtering, has been
said to occur directly in visual regions such as V1 and V4 (Chun & Wolfe, 2000) - regions
previously discussed as containing 5HT2A receptor site expression (Shimegi et al., 2016). While
the subject of attention modulation as a whole poses distinct hurdles in the complex neural
mapping of its many possible loci, the underlying cortical systems associated with attention and
visual processing seem to appear inclusive of 5HT2A activity, which can then be focused on.

Integrating Pharmacology and Attention
Past laboratory research of the effects of psychoactive drugs on cognition and attention
already has a history within research on Attention Deficit Hyperactivity Disorder. The effects of
stimulants (nicotine, cotinine, methylphenidate, caffeine) on information processing is a
repeatedly discussed measure, and has indicated general improvements to aspects like reaction
time (RT) (Callaway et al., 1985; Naylor et al., 1985; Koelega, 1992; Herzig et al., 1997; Rycroft
et al., 2004; Tucha et al., 2005; Advokat, 2010). Methylphenidate is one of the most prominent
medications prescribed for attention disorders, and is specifically associated with decreases in
RT (Naylor et al., 1985), and benefits to focused attention (Tucha et. al., 2005). Thus, given the
biological basis for 5HT receptor modulation in attention-based regions like the visual system
and PFC, the designs originally used to test the effects of stimulants may also be effective
templates to use in measuring the effect psychedelic microdosing has on cognition and
information processing.
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Because cognitive research on psychedelic microdosing is still in its infancy, there are
conflicting reports right now about its efficacy due to the limited number of measures that have
actually been tested. Also, much of the research on microdosing is all still first of its kind,
meaning that following a particular publication, not enough time has lapsed for other researchers
to similarly reproduce experiments. It seems as though it may simply require more time for
enough microdosing research to be produced, so that research areas where it holds significance,
if any, are thoroughly categorized. Until this occurs, the documented research has varied in
outcome depending on whether it is focused on qualitative or quantitative attributes.
From a qualitative perspective, certain measures that have been integrated into survey
studies have focused on aspects of a person’s perceived productivity, which could be associated
with their ability to attend to a task. Work conducted by Fadiman & Korb (2019), showed that
microdosing enabled subjects to better attend to the task at hand, with less procrastination, and
conclude their work (Fadiman & Korb, 2019). Also, Polito and Stevenson (2019), used a
preliminary, multi-measure evaluation of personality characteristics, mood, and focus, on
participants who were microdosing. This included a specific questionnaire on mind wandering
(MWQ). The hindrance of mind wandering, also known as daydreaming, is a common and
debilitating disruption in attentional processing, thought to be activated when an individual’s
default mode network in the brain begins to override and disrupt mental functions on a task
requiring one’s attention (Goldstein, 2019). Polito and Stevenson (2019) found significant
declines in MWQ scores after microdosing. Such reports provided the early evidence that
psychedelic microdosing may enhance aspects of attention.
Most recently, the meager number of experiments studying quantitative differences in
microdosing performance has finally started to increase. This has entailed research happening
8

under uniquely devised conditions like the novel citizen-science approach discussed earlier, and
also conducting clinically controlled experiments in geographic locales where the conduct of
psychedelic research is more welcomed. In a new study published around the time this project
was being developed, 24 participants in the Netherlands were recruited for testing the minimal
thresholds of LSD needed to modulate cognitive processes and mood alterations (Hutten et al.,
2020). Part of the reasoning for this study was to evaluate the anecdotal reports of microdosing’s
cognitive enhancing capabilities. As such, several cognitive measures were evaluated. The study
reported mixed results in terms of the cognitive effects of microdosing. On tasks of cognitive
control, no significant differences were documented (Hutten et al., 2020). While on psychomotor
vigilance tasks, significant reductions in Dose by Participant attentional lapses at 5 micrograms
(mcg) and 20 mcg were observed, although no main dose effect was found (Hutten et al., 2020).
A slight, but not significant, reduction in reaction time (RT) was also observed (Hutten et al.,
2020).
Reproducibility of any of the studies mentioned in this discussion has yet to be embarked
upon. It is evident by noting the citations, that most of the research on microdosing has only
emerged over the last two years. Thus, if we are to continue embarking on future microdosing
research, it will be necessary to reproduce the studies that have been mentioned, while also
developing additional paradigms to test microdosing’s effects under. When considering that
cognitive research of psychostimulants has been ongoing for decades under the umbrella of
attention disorder research, the designs of those studies may additionally complement questions
about the efficacy of psychedelic microdosing. It has been previously shown that
psychostimulants such as amphetamine (Adderall) and methylphenidate (Ritalin) have
significantly speeded cognitive performance on measures of information processing through
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noradrenergic and dopaminergic mechanisms (Koelega, 1993). Using the historical evidence for
psychostimulants, a basis for reviving similar research designs to test the cognitive effects of
psychedelic microdosing can now be established in the modern day. In exchange for rate of
performance, psychostimulants have also been shown to potentially impair other aspects of
attention, like information acquisition and cognitive flexibility (Advokat, 2010). A reasonable
question to ask is whether psychedelic microdosing may offer similar improvements, but without
reductions in flexibility.
The current study aimed to create such a framework by reproducing a task used to test
psychostimulants on information processing in decades prior. Because individuals are utilizing
psychedelic microdosing as a potential productivity enhancer, how microdosing affects
information processing becomes essential in understanding its efficacy. The anecdotal reports of
enhanced productivity, plus the understanding that classical psychedelics induce effects on visual
perception and cortical regions devoted to attention via 5HT2A modulation, acts as the foundation
upon which this type of research can be based. Here, we tested the hypothesis that psychedelic
microdosing causes an enhancement in task performance through the implementation of a
simple/choice serial response task, evaluating target selection at different difficulties and
response selection at different difficulties. The study involved a between-subjects design that
compared the performance of a microdosing condition against a control condition. Distributions
of RT and target accuracy were analyzed for measures of effect size, statistical significance, and
variance.
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METHOD
Participants
A total of 19 anonymous participants were recruited to comprise the two independent
groups. 12 participants initially made up the control group, recruited within the UCF student
body through SONA. To form the experimental microdosing group, seven participants were
initially recruited via an online listing that was shared on various microdosing forums. The
specific list of forums where the study link was shared is included in Appendix A.
Personal invitations indicating where the study could anonymously be located on Reddit were
also distributed to friends and acquaintances of the researcher, should those individuals have
been partaking in the act of microdosing.
Exclusionary criteria were dependent on the particular group a participant was recruited
into. For the control, a single-question survey at the beginning of the task evaluated age (see
Appendix B). For the microdosing group, the age question was followed by a series of questions
evaluating the individual’s microdosing practices (see Appendix B). Age criteria was based on a
range of 21 – 45 years. The age cap controlled for potential differences between the groups, since
there was a possibility that the control group, comprised of university students, may be
substantially younger than the microdosing participants recruited online. Age-related vision
deficits such as presbyopia become more common in populations older than 45, and thus this was
the chosen cap (American Optometric Association, n.d.). For participants included within the
analysis, control group ages ranged from 21 to 38 years (M = 24.40, SD = 5.48), and
microdosing group ages ranged from 27 to 41 years (M = 32.50, SD = 6.19). Additional
questions included in the microdosing version of the experiment determined the type of
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substance being microdosed, estimated dosage of the substance, and whether or not the
participant had administered the dose between two to four hours prior to accessing the
experiment. Only LSD and psilocybin were acceptable responses. The minimum and maximum
dosages classified as a microdose were: psilocybin mushrooms (min. 0.1 g – max. 1.5 g); LSD
(min. 1.4 mcg – max. 50 mcg). Dosages outside the range resulted in a failure to meet study
criteria. Such dosages were established in line with prior microdosing studies (Polito &
Stevenson, 2019). A summary of participant substances and dosages is included in Table 1.

Table 1: Participant Dosages and Substances

Participant
13
14
15
16
LSD Average
Psilocybin Average

Substance
LSD
Psilocybin
LSD
LSD

Dosage
8
0.5
6
7
7
0.5

Units
Micrograms
Grams
Micrograms
Micrograms
Micrograms
Grams

Material
The experiment was designed using PsychoPy3 Experiment Builder (v2020.2.10) (Peirce
et al., 2019). The task was designed in such a manner to be run only on desktop computers and
laptop computers equipped with keyboards. Both Windows and MacOs operating systems were
functionable with the experiment. Upon design completion, the experiment was uploaded to
Pavlovia.org where it was accessible to participants.
The exact task participants had to complete is known as the Stimulus
Evaluation/Response Selection Task (SERS task) (Callaway et al., 1985; Herzig et al., 1998;
Naylor et al., 1985). The SERS task is a behavioral design that measures simple and choice RT,
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depending on the trial condition. Usually, two levels of difficulty for target identification and two
levels of difficulty for response selection are incorporated. Trial blocks are represented by a
series of naming conventions, either “Easy” (E) or “Hard” (H), for both target-identification type
and response type. An easy stimulus is represented by a single X-shaped target without
additional distractor stimuli surrounding it, while a hard stimulus is represented by an X-shaped
target with other star-shaped distractor(s) also in the display (see Figure 1). An easy response
type involves pressing a standalone button to acknowledge identification of a target, while a hard
response type involves a specific button selection, to acknowledge target identification, and also
the exact position of the target within the display. As an example of the naming convention, a
trial block with a hard stimulus selection, but easy response type, would be denoted as “HE”.
With this combination, a total of four conditions, measuring both stimulus evaluation, and
response selection can be observed (EE, EH, HE, HH). The SERS task also involves catch trials
placed throughout the task, in which the participant is to make no button response, but instead
allow the trial to self-terminate after five seconds (see Figure 1). Catch trials were included as a
further measure of diligence.

13

Easy Trial

Hard Trial

Easy Catch

Hard Catch

Figure 1: Examples of the various displays incorporated into the experiment

Procedure
Following a participant’s informed consent and completion of the exclusionary criteria
questionnaires, they were next introduced to a series of instruction screens which provided
details about the experimental task. They were then given a set of five practice trials for each of
the four trial conditions prior to beginning the experimental trials. Participants were provided
with a notice screen before the start of each block indicating the response difficulty they were
being assigned in that block. The two response levels of difficulty included the “Easy Response”
condition - use of the space bar to indicate the presence of a target - or the “Hard Response”
condition - use of the “D”, “F”, “J”, “K” keys to signal a choice response for target identification
plus position. To further elaborate on this Hard Response condition, participants were instructed
to maintain normal typing position over the keyboard, and press the key that related to the
target’s position on the screen. For example, if a participant was in the Hard Response condition,
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if the target was located furthest to the left, they would press the “D” key; if the target was
located second-most to the right, they would press the “J” key, and so forth. A red warning
message was coded into the experiment letting the participant know if they were beginning to
use the wrong response set for the particular trial condition they were in.
The full experiment contained eight blocks of trials – two blocks for each of the four trial
conditions. Blocks were shown in a sequence to match that of the original SERS study designs
(EE, EH, HE, HH, HE, HH, EE, EH) (Naylor et al., 1985; Callaway et al., 1985). There were 30
trials per block, presented in a randomized but balanced fashion. Potential target positions in the
displays, plus catch trials, were evenly divided, representing a twenty-percent frequency for each
target position plus catch trials. A total of 240 trials comprised the experiment. A break screen
was placed in between each of the blocks notifying the participant that they may now take a
break before beginning the next block. The break screen was also the notification screen that told
the participant which response difficulty the next block entailed. The total experiment was
estimated to last roughly 25 minutes, including instruction screens and practice trials. Lastly, the
experiment concluded with a debriefing message thanking the participant, notifying them the
experiment was over. An honesty check was also included on the final debriefing page asking if
the participant had properly completed the task. Specific parameters around whether the data
should have been utilized included whether or not the participant experienced prolonged
distractions during the task, did not effortfully apply themselves, or if they had already
participated in the experiment before. The participant then answered whether they thought the
researchers should use their data in the analysis by clicking a Yes/No radio button (see
Appendix C).
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RESULTS
Data output files were downloaded from Pavlovia.org and organized using Microsoft
Excel. Before performing the analysis, several participants were removed from the final samples.
Two participants from the control group disclosed a failure to properly complete the task, and so,
their data was removed. This left a total of 10 control participants to be analyzed within the
analysis (Ncontrol = 10). Two participants within the experimental group failed to properly cycle
through the different response levels of the task, and a third participant failed to interpret the
catch trial responses correctly. All three data sets were removed from the final analysis (Nexp =
4).
The sorted data files were then fed into SPSS (v27) for statistical analysis. A 2×2×2
repeated measures ANOVA with mixed factors was first computed on RT data, with one
between-subjects factor (Microdosing vs. Control) and two within-subjects factors (Easy Target
vs. Hard Target; Easy Response vs. Hard Response). No main effect was found between the two
experimental conditions (F(1,12) = 1.53, p = .24, ƞp2 = .11). Within-subjects analysis revealed a
moderate but significant effect between the two target difficulties (F(1,12) = 10.17, p = .008, ƞp2
= .459), indicating that the levels of difficulty between the simple and hard targets in the
experiment, with the presence of distractor images in the hard conditions, were working as
designed. However, between Easy and Hard response conditions, no significant effect was
observed. This indicates that whether using the space bar, or using the lettered keys throughout
the different blocks of the experiment did not hinder the performance of participants. There were
no significant interactions. Additionally, comparison of the mean RTs from both samples showed
an overall faster RT within the control sample (M = 633.54 ms, SD = 142.25), than that of the
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microdosing sample (M = 766.31ms, SD = 278.11) (see Figure 2). Although no significance can
be gathered from analysis of the variances between the two groups, this trend in longer RT from
the microdosing group indicates that within the scope of this analysis, performance from the
microdose group pointed in the opposite direction from that of the hypothesis.
Between-subjects effects of number of correct trials and correct catch trials were also
analyzed. In reviewing these measures, no significant effects were identified in the number of
correct catch trials between the two groups (p = .32, ƞp2 = .09), but a slightly larger effect of
correct trials was seen between the two samples (F(1,12) = 2.5, p = .140, ƞp2 = .172). Importantly
however, when observing the mean correct trial counts across all target and response conditions
for each sample, the control group averaged roughly one more correct trial (M = 47.28, SD =
1.15) when compared to the microdosing group (M = 46.38, SD = 1.96) (see Figure 2). This
means that the effect on correct trials, specific to the scope of this analysis, showed a decrease in
accuracy from the microdosing group, again moving in an opposite direction to the hypothesis.
Graphs for the individual experimental conditions have also been included within Figure 3. A
final critical aspect to note when discussing this analysis was the minimal number of
participants. Thus, when running an observed power test between the experimental and control
groups, observed power for the experiment was low (.207), highlighting a need for larger sample
sizes.
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Figure 2: The left bar chart represents mean reaction times (RT) for each group across all conditions (EE, EH, HE,
HH). The right bar chart represents mean number of correct trials for each group across all conditions. Note correct
trials does not include the 20% catch trials which were measured separately. Error bars represent one standard
deviation above and below the mean.

Figure 3: The top bar chart
represents mean RT for each
group by experimental
condition.
The bottom bar chart
represents men number of
correct trials for each group
by experimental condition.
Error bars represent one
standard deviation above and
below the mean.
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DISCUSSION
The hypothesis for this study was developed to test whether microdosing classical
psychedelics could produce observable improvements in measures of information processing.
Since microdosing has become increasingly popular for a variety of reasons including the
potential enhancement of cognition, research on the matter is warranted from a practical
perspective. The findings from this particular study did not end up supporting the hypothesis
however. Crucially, at the start of the recruitment period, it was unknown whether participant
turnout for the study would be substantial or limited. The recruitment period for the study was
just over four weeks long, and although there were more than two-hundred registered clicks
accessing the experiment, only seven microdosers fully completed the task. For future studies
attempting to utilize online recruitment methods, additional time should be allocated to ensure
desired sample sizes are acquired. Given the increased difficulty in online recruitment above
what had been originally anticipated, results of the analysis were derived from too small of a
sample to hold statistical power, limiting the sensitivity of the experiment in determining
whether such effects actually exist. This study represents an example of some of the difficulties
that anonymous online recruiting faces.
By observing some of the basic properties in the trends of the data though, ideas may still
be intuited upon which can be developed into future research projects. Although it was not
statistically significant, observations of mean RT indicated slower responses and less accuracy in
the microdosing sample from that of the control. How this compares to other scientific findings
about the function of 5HT in the brain may actually still depict an otherwise accurate
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representation of the changes in physiological processes that occur when using psychedelics, but
without the necessary data in this instance to be confirmed.
Earlier research on the effects of SSRIs on attention has provided a link between changes
to 5HT activity and impairments in various attention tasks (Wingen et al., 2007; Oranje et al.,
2008). Furthermore, research on the relationship between psilocybin-induced visual
hallucinations and 5HT2A, found heightened activation of the receptor site correlated to decreases
in α brain wave oscillations in the parieto-occipital cortex (Kometer et al., 2013). Such brain
wave activity is considered necessary for evaluating visual stimuli. Although Kometer et al.,
(2013) did not document significant differences in RT between psilocybin-only and psilocybinketanserin antagonist conditions on their cognitive task, a significant finding of increased error
rate was observed in the psilocybin-only condition. This points to a potentially negative, rather
than beneficial, outcome for attentional processing in situations where excitatory serotonergic
modulation is occurring. Because Kometer et al., (2013) was focused on intentionally inducing
visual effects related to psilocybin, rather than assessing performance variations at the microdose
level, the exact context makes it difficult to generally apply the results of this experiment to the
microdosing paradigm. Such findings however, do provide convincing grounds on which to build
a microdosing hypothesis alternate to that of the current study. Even within the present analysis,
it was seen that target difficulty played a role in RT, above which the microdosing sample then
performed additionally slower in. If a disruptive relationship due to over-excited 5HT2A similarly
holds true for modulation at the microdose level, decreased RT or higher error rates could instead
be inferred as the predicted outcome of such experimentation. Along with this alternate
hypothesis, another good research question to additionally ask is whether there are threshold
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levels of psychedelic dosages where paradoxical effects in information processing begin to
emerge.
If no significant benefit occurs in cognitive enhancement from microdosing, which is still
yet to be fully determined, where might this leave the qualitative studies that have documented
the differences in reports filled out by microdosing participants? Although people may
subjectively interpret perceptual changes from microdosing as “enhancing”, shifts in perspective
about a task or their relative performance compared to normal waking states may simply be
associated with a type of novelty for how they conduct themselves while microdosing, rather
than be evidence for direct changes in performance. Such an interpretation would align with the
recent findings that perceived benefits from the practice of microdosing could similarly be
associated with a placebo effect (Szigeti et al., 2021). In hindsight, one potential feature that
could have been built into this study to measure such potential effect, would have been an
additional follow-up survey after the task, asking participants in both groups to rate how well
they thought they performed. The results of the survey could have similarly been measured for
any differences in response between the groups.
A defense for null results or inhibited performance on information processing and speed
of cognition associated with microdosing is far from the only type of use case where this practice
should be evaluated though. While the primary objective for this study related specifically to
cognitive enhancement, many of the referenced publications have designed studies that also
focus on other potential effects of psychedelic microdosing separate from that to cognition
(Hutten et al., 2020; Polito & Stevenson, 2019; Fadiman & Korb, 2019). A particular measure
that has been replicated across several studies is the 5 Dimensions of Altered States of
Consciousness Questionnaire (5D-ASC) (Kometer et al., 2013; Bershad et al., 2019; Hutten et
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al., 2020). In both Bershad et al., (2019) and Hutten et al., (2020), results from microdosing
showed significant changes in responses to dimensions of the questionnaire described as
“Oceanic Boundlessness” and “Anxious Ego Dissolution”. Inferring on these effects in the 5DASC highlights a possibility that future brain imaging research for microdosing could find its
most important discoveries in the context of subjects like anxiety reduction, creativity, and
abstract thinking, rather than as an alternative cognitive enhancer or treatment for attention
disorders.
What is clear about the use of psychedelics currently, is a recent shift in interests from the
general public as well as the scientific research community. A long hiatus from clinical testing
and research has meant that several generations of scientists who may have otherwise chosen to
delve into this field perhaps did not. Their potential discoveries for the useful and insightful
applications of psychedelic compounds remain shelved as part of the unknown, yet-to-bediscovered future for the fields of medicine, and perhaps society at large. This study’s focus on
the effects of psychedelic microdosing did not yield significant results, but can still be of use in
motivating other researchers to improve upon it, and create new designs that involve the use of
technology and the internet to effectively open up behavioral research to much larger audiences.
On one hand, there is definitive evidence of the neurobiological changes that classical
psychedelics can induce in the brain, given sufficient dosages to result in drastic changes to
visual perception, spiritual outlook, emotions, moods, and perspectives about the world. On the
other hand, the practice of microdosing with these substances aims to keep the user in the driver
seat, such that they can make practical use out of these experiences to fit their daily lives. The
varying levels at which people use psychedelic compounds creates a continuous scale that entails
a large range of potential outcomes. Further research will be needed to determine whether
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various thresholds exist for different applications of psychedelic compounds, including for the
use of cognitive enhancement. It is a process that will need to play catch up for the last several
decades that have been lost to this field of research, but may perhaps become increasingly
important for us to determine scientifically, so that we do not become limited in the potential
tools we use for understanding the workings of the brain.
In summary, this study aimed to assist in reintroducing psychedelic research from a
cognitive perspective, based upon anecdotal reports of the effects of psychedelic microdosing
and an understanding of how classical psychedelics modulate neural function. A behavioral
research design once used in pharmacological attention research was recreated using modern
psychological software so that it could be shared anonymously through online means. The study
exemplifies some of the necessary strategies researchers will need utilize when designing such
experiments, until the heavy restrictions for working with psychedelics are lifted. Cognitive
enhancement within the microdosing sample was not documented in this study. Instead, a
potential finding of contrasting effects from that of the hypothesis may be present. In conjunction
with findings from other research on 5HT and its neuromodulators (both SSRI’s and
psychedelics), indication of potential lapses or decreases in attentional capabilities may provide
the basis for future research to form alternative hypotheses regarding psychedelic microdosing
and its effects on information processing. Other research areas for the application of
microdosing, such as creativity perspective, mood enhancement, or anxiety reduction were not
tested within this study, and represent several other avenues for which psychedelic microdosing
could benefit from future research as well.
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APPENDIX A
PSYCHEDELIC MICRODOSING RECRUITMENT FORUMS

24

•

Reddit.com (https://www.reddit.com/r/microdosing)
o (https://www.reddit.com/r/Psychedelics)
o (https://www.reddit.com/r/PsychedelicStudies)
o https://www.reddit.com/r/Nootropics)

•

Bluelight.org (https://www.bluelight.org/xf/forums/drug-studies.180/)

•

Facebook.com (https://www.facebook.com/groups/PsychedelicsToday)
o (https://www.facebook.com/groups/Psychedelic.Heaven)
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APPENDIX B
EXCLUSIONARY CRITERIA QUESTIONNAIRES
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Age Question (Both Control & Experimental Group)
1. “Please state your age in years (NUMBERS ONLY).”

Exclusionary Criteria Questions (Experimental Microdosing Group)
1. “Please state the substance you are using today (PSILOCYBIN or LSD only).”
2. “Please state the estimated dosage of the substance you are using today.”
3. “The study request microdosing participants perform the experiment after a recently
administered microdose.
Can you confirm you are participating between 2-4 hours after administration of your
microdose?
Only YES/NO responses please.”
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APPENDIX C
HONESTY CHECK DEBRIEFING PAGE
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Honesty Check Text
Thank you so much! The experiment has ended.
Before leaving though, we would like to ask some final questions about your performance
today.
Because of the remote nature of this experiment, we understand that circumstances may
arise which can affect the quality of your work.
Please consider the following questions, then respond to the final question below:
- Did I experience any distractions today that affected my performance on the task?
- Did I effortfully apply myself throughout the entirety of the task?
- Is this the first and only time I have performed this experiment?
With the above questions in mind, should the researchers of this project proceed to utilize
your data from today's trials?

Yes

No
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